| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Catherine Pellat-Deceunynck | |
| Régis Bataille | |||
| Isabelle Bekeredjian-Ding | |||
| Gaëtan Jego | |||
| David Chiron | |||
| P2860 | cites work | Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6 | Q24317429 |
| Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function | Q24317859 | ||
| Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling | Q24684997 | ||
| Pathogen recognition and innate immunity | Q27861084 | ||
| TLR signaling | Q28291637 | ||
| Immunosuppressive networks in the tumour environment and their therapeutic relevance | Q29619244 | ||
| Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy | Q29619961 | ||
| Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE | Q29620722 | ||
| Toll-like receptor expression and responsiveness of distinct murine splenic and mucosal B-cell subsets | Q30834266 | ||
| Toll-like receptor 2-mediated human B cell differentiation | Q33246383 | ||
| Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity | Q34491896 | ||
| The molecular classification of multiple myeloma | Q34530992 | ||
| Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide | Q34531452 | ||
| Toll-like receptors in systemic autoimmune disease | Q34576448 | ||
| IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients | Q34657691 | ||
| Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia | Q35642807 | ||
| Endogenous ligands of Toll-like receptors | Q35792678 | ||
| Modulating vaccine responses with dendritic cells and Toll-like receptors | Q35826412 | ||
| Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells | Q35848756 | ||
| Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma | Q35849633 | ||
| Tolerance, not immunity, crucially depends on IL-2. | Q35877199 | ||
| Heparan sulfate proteoglycans and heparanase--partners in osteolytic tumor growth and metastasis. | Q35943349 | ||
| T-independent activation-induced cytidine deaminase expression, class-switch recombination, and antibody production by immature/transitional 1 B cells | Q35955998 | ||
| Dendritic cells control B cell growth and differentiation | Q35963666 | ||
| Failure of B Cells of Chronic Lymphocytic Leukemia in Presenting Soluble and Alloantigens | Q61657716 | ||
| Respiratory tract infections in the pathway to multiple myeloma: a population-based study in Scandinavia | Q61826842 | ||
| Staphylococcus aureus Protein A Triggers T Cell-Independent B Cell Proliferation by Sensitizing B Cells for TLR2 Ligands | Q63408461 | ||
| Loxoribine induces chronic lymphocytic leukemia B cells to traverse the cell cycle | Q72776641 | ||
| Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells | Q73386737 | ||
| CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens | Q73492223 | ||
| Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype | Q73795158 | ||
| A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells | Q78863058 | ||
| TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses | Q80427941 | ||
| Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses | Q81223194 | ||
| B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides | Q81474815 | ||
| Toll-like receptors, endogenous ligands, and systemic autoimmune disease. | Q36079856 | ||
| Class switch recombination and somatic hypermutation in early mouse B cells are mediated by B cell and Toll-like receptors | Q36151542 | ||
| B cell intrinsic TLR signals amplify but are not required for humoral immunity | Q36294387 | ||
| Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia | Q36635059 | ||
| Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. | Q36641814 | ||
| Regulation of TLR4 signaling and the host interface with pathogens and danger: the role of RP105. | Q36807091 | ||
| Human Toll-like receptor-dependent induction of interferons in protective immunity to viruses | Q36990637 | ||
| Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity | Q36990647 | ||
| Toll-like receptor 9 (TLR9) agonists in the treatment of cancer | Q37050998 | ||
| TLR2 - promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity | Q37136130 | ||
| Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides | Q38289912 | ||
| CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response | Q38332055 | ||
| Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. | Q38333437 | ||
| The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells | Q38355683 | ||
| Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. | Q40005494 | ||
| TLR7 and CD40 cooperate in IL-6 production via enhanced JNK and AP-1 activation. | Q40019462 | ||
| Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors | Q40289625 | ||
| Toll-like receptors mediate proliferation and survival of multiple myeloma cells | Q40291993 | ||
| HMGB1 expression and release by bone cells | Q40328332 | ||
| Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia. | Q40330092 | ||
| CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. | Q40512685 | ||
| Immunology: Toll-like receptors and antibody responses | Q42125203 | ||
| Cutting edge: Lipopolysaccharide induces IL-10-producing regulatory CD4+ T cells that suppress the CD8+ T cell response | Q42631213 | ||
| Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients | Q42742001 | ||
| Memory B cells are biased towards terminal differentiation: a strategy that may prevent repertoire freezing | Q42951748 | ||
| Antibody-dependent induction of type I interferons by poliovirus in human mononuclear blood cells requires the type II fcgamma receptor (CD32). | Q43768979 | ||
| Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. | Q43845859 | ||
| Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents | Q43881315 | ||
| Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. | Q44052611 | ||
| MyD88 is required for the formation of long-term humoral immunity to virus infection | Q45405612 | ||
| Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. | Q46391163 | ||
| Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod | Q46600658 | ||
| Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells | Q46845154 | ||
| Overcoming immune tolerance against multiple myeloma with lentiviral calnexin-engineered dendritic cells | Q48032304 | ||
| TLR9 stimulation drives naïve B cells to proliferate and to attain enhanced antigen presenting function. | Q51973780 | ||
| A distinct Toll-like receptor repertoire in human tonsillar B cells, directly activated by PamCSK, R-837 and CpG-2006 stimulation. | Q51981691 | ||
| Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. | Q51996837 | ||
| Maintenance of serological memory by polyclonal activation of human memory B cells. | Q52008907 | ||
| The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. | Q53595110 | ||
| Toll-like receptor stimulation as a third signal required for activation of human naive B cells. | Q53632191 | ||
| Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity. | Q53633872 | ||
| Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. | Q55043619 | ||
| Cytotoxic combination of loxoribine with fludarabine and mafosfamide on freshly isolated B-chronic lymphocytic leukemia cells | Q57012928 | ||
| Control of B-cell responses by Toll-like receptors | Q59066168 | ||
| FcγRIIb controls bone marrow plasma cell persistence and apoptosis | Q60268649 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | toll-like receptor | Q408004 |
| P304 | page(s) | 2205-2213 | |
| P577 | publication date | 2008-06-30 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Toll-like receptors: lessons to learn from normal and malignant human B cells | |
| P478 | volume | 112 |
| Q28729093 | An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy |
| Q38094250 | B-lymphocyte lineage cells and the respiratory system |
| Q37480851 | B7-1/2 (CD80/CD86) direct signaling to B cells enhances IgG secretion. |
| Q48004637 | CD180 expression in B-cell lymphomas: A multicenter GEIL study |
| Q56964097 | CD180 functions in activation, survival and cycling of B chronic lymphocytic leukaemia cells |
| Q34673706 | Characterization of the Toll-like receptor expression profile in human multiple myeloma cells |
| Q37053088 | Circulating human antibody-secreting cells during vaccinations and respiratory viral infections are characterized by high specificity and lack of bystander effect |
| Q85952940 | Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system |
| Q51901055 | Differential expression of Toll-like receptors in follicular lymphoma, diffuse large B-cell lymphoma and peripheral T-cell lymphoma. |
| Q37144548 | Distinct Differentiation Programs Triggered by IL-6 and LPS in Teleost IgM(+) B Cells in The Absence of Germinal Centers. |
| Q36781293 | Dysregulated B-cell TLR2 expression and elevated regulatory B-cell frequency precede the diagnosis of AIDS-related non-Hodgkin lymphoma |
| Q37772578 | Endogenous toll-like receptor ligands and their biological significance |
| Q37952071 | Exogenous or endogenous Toll-like receptor ligands: which is the MVP in tumorigenesis? |
| Q42005623 | Global gene expression changes of in vitro stimulated human transformed germinal centre B cells as surrogate for oncogenic pathway activation in individual aggressive B cell lymphomas |
| Q37671216 | Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application |
| Q35693948 | IRF-4 suppresses BCR/ABL transformation of myeloid cells in a DNA binding-independent manner |
| Q34154994 | In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. |
| Q37997024 | Innate immunity and hepatitis C virus infection: a microarray's view |
| Q36271580 | Integrin-dependent cell adhesion to neutrophil extracellular traps through engagement of fibronectin in neutrophil-like cells |
| Q37318226 | Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. |
| Q37352480 | Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses. |
| Q34462647 | Macropinocytosis is responsible for the uptake of pathogenic and non-pathogenic mycobacteria by B lymphocytes (Raji cells) |
| Q58754109 | Multiple Myeloma Exemplifies a Model of Cancer Based on Tissue Disruption as the Initiator Event |
| Q41786115 | Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice. |
| Q35140039 | Pellino 1 promotes lymphomagenesis by deregulating BCL6 polyubiquitination. |
| Q42210954 | Peroxisome proliferator-activated receptor gamma ligands enhance human B cell antibody production and differentiation |
| Q51888725 | Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. |
| Q34495557 | Revisiting the B-cell compartment in mouse and humans: more than one B-cell subset exists in the marginal zone and beyond. |
| Q29547203 | STATs in cancer inflammation and immunity: a leading role for STAT3 |
| Q28284022 | Sphingosine-1-phosphate suppresses TLR-induced CXCL8 secretion from human T cells |
| Q46189367 | Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control |
| Q41876189 | Stimulation of Toll-like receptor-1/2 combined with Velcade increases cytotoxicity to human multiple myeloma cells |
| Q38743752 | Synergy of interleukin 10 and toll-like receptor 9 signalling in B cell proliferation: Implications for lymphoma pathogenesis. |
| Q64896109 | TLR2 Expression on Leukemic B Cells from Patients with Chronic Lymphocytic Leukemia. |
| Q48918903 | TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma |
| Q36071989 | TLR9 agonists induced cell death in Burkitt's lymphoma cells is variable and influenced by TLR9 polymorphism |
| Q37991536 | Targeting pattern recognition receptors in cancer immunotherapy. |
| Q36716822 | The Role of PPARs in Placental Immunology: A Systematic Review of the Literature |
| Q34021580 | The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals |
| Q37583889 | The role of polymorphisms in Toll-like receptors and their associated intracellular signaling genes in measles vaccine immunity |
| Q38665495 | The role of toll-like receptors in B-cell development and immunopathogenesis of common variable immunodeficiency |
| Q35920787 | Therapeutic Toll-like receptor agonists directly influence mouse and human T cell lymphoma cell viability and cytokine secretion |
| Q36001708 | Toll-Like Receptor 1/2 and 5 Ligands Enhance the Expression of Cyclin D1 and D3 and Induce Proliferation in Mantle Cell Lymphoma. |
| Q28538422 | Toll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosis |
| Q34602046 | Toll-like receptor 2 is required for autoantibody production and development of renal disease in pristane-induced lupus |
| Q37831323 | Toll-like receptor 9 agonists as cancer therapeutics |
| Q55006191 | Toll-like receptor expression and function differ between splenic marginal zone B cell lymphoma and splenic diffuse red pulp B cell lymphoma. |
| Q38238963 | Toll-like receptors in the pathogenesis of human B cell malignancies |
| Q33494116 | Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation |
| Q38948266 | Toll-like receptors targeting technology for the treatment of lymphoma |
| Q37672658 | Toll-like receptors--sentries in the B-cell response |
| Q40273988 | What do we know about the role of regulatory B cells (Breg) during the course of infection of two major parasitic diseases, malaria and leishmaniasis? |
Search more.